Annual Shareholders Equity
-$4.86 M
-$1.84 M-61.13%
December 31, 2023
Summary
- As of February 8, 2025, BCLI annual stockholders equity is -$4.86 million, with the most recent change of -$1.84 million (-61.13%) on December 31, 2023.
- During the last 3 years, BCLI annual shareholders equity has fallen by -$40.32 million (-113.70%).
- BCLI annual shareholders equity is now -113.70% below its all-time high of $35.46 million, reached on December 31, 2020.
Performance
BCLI Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
-$6.06 M
-$2.53 M-71.73%
September 30, 2024
Summary
- As of February 8, 2025, BCLI quarterly stockholders equity is -$6.06 million, with the most recent change of -$2.53 million (-71.73%) on September 30, 2024.
- Over the past year, BCLI quarterly shareholders equity has dropped by -$2.53 million (-71.73%).
- BCLI quarterly shareholders equity is now -116.73% below its all-time high of $36.20 million, reached on March 31, 2021.
Performance
BCLI Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
BCLI Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -61.1% | -71.7% |
| 3 y3 years | -113.7% | -71.7% |
| 5 y5 years | -196.8% | -71.7% |
BCLI Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -125.1% | at low | -131.3% | at low |
| 5 y | 5-year | -113.7% | +60.3% | -116.7% | +50.5% |
| alltime | all time | -113.7% | +60.3% | -116.7% | +50.5% |
Brainstorm Cell Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -$6.06 M(+71.7%) |
| Jun 2024 | - | -$3.53 M(-36.5%) |
| Mar 2024 | - | -$5.55 M(+14.2%) |
| Dec 2023 | -$4.86 M(+61.1%) | -$4.86 M(+88.1%) |
| Sep 2023 | - | -$2.58 M(-33.5%) |
| Jun 2023 | - | -$3.88 M(-19.8%) |
| Mar 2023 | - | -$4.84 M(+60.5%) |
| Dec 2022 | -$3.02 M(-115.6%) | -$3.02 M(-317.2%) |
| Sep 2022 | - | $1.39 M(-82.3%) |
| Jun 2022 | - | $7.85 M(-45.8%) |
| Mar 2022 | - | $14.49 M(-25.1%) |
| Dec 2021 | $19.34 M(-45.5%) | $19.34 M(-22.4%) |
| Sep 2021 | - | $24.93 M(-17.4%) |
| Jun 2021 | - | $30.17 M(-16.7%) |
| Mar 2021 | - | $36.20 M(+2.1%) |
| Dec 2020 | $35.46 M(-390.1%) | $35.46 M(+36.5%) |
| Sep 2020 | - | $25.98 M(+164.5%) |
| Jun 2020 | - | $9.82 M(+9.0%) |
| Mar 2020 | - | $9.01 M(-173.7%) |
| Dec 2019 | -$12.22 M(-343.7%) | -$12.22 M(+80.4%) |
| Sep 2019 | - | -$6.78 M(+50.1%) |
| Jun 2019 | - | -$4.52 M(-1485.3%) |
| Mar 2019 | - | $326.00 K(-93.5%) |
| Dec 2018 | $5.02 M(-14.7%) | $5.02 M(-49.7%) |
| Sep 2018 | - | $9.98 M(-22.5%) |
| Jun 2018 | - | $12.87 M(+235.8%) |
| Mar 2018 | - | $3.83 M(-34.8%) |
| Dec 2017 | $5.88 M(-40.6%) | $5.88 M(+13.2%) |
| Sep 2017 | - | $5.20 M(-28.7%) |
| Jun 2017 | - | $7.29 M(-11.6%) |
| Mar 2017 | - | $8.24 M(-16.8%) |
| Dec 2016 | $9.90 M(-29.9%) | $9.90 M(-5.9%) |
| Sep 2016 | - | $10.53 M(-11.3%) |
| Jun 2016 | - | $11.87 M(-5.6%) |
| Mar 2016 | - | $12.57 M(-11.0%) |
| Dec 2015 | $14.13 M(+111.7%) | $14.13 M(-9.0%) |
| Sep 2015 | - | $15.52 M(-13.0%) |
| Jun 2015 | - | $17.84 M(-9.3%) |
| Mar 2015 | - | $19.66 M(+194.5%) |
| Dec 2014 | $6.67 M(+143.7%) | $6.67 M(-25.0%) |
| Sep 2014 | - | $8.90 M(-16.0%) |
| Jun 2014 | - | $10.60 M(+1132.6%) |
| Mar 2014 | - | $860.00 K(-68.6%) |
| Dec 2013 | $2.74 M | $2.74 M(-39.6%) |
| Sep 2013 | - | $4.54 M(+92.6%) |
| Jun 2013 | - | $2.35 M(-32.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $3.48 M(-12.6%) |
| Dec 2012 | $3.98 M(+167.6%) | $3.98 M(-10.7%) |
| Sep 2012 | - | $4.46 M(+1662.5%) |
| Jun 2012 | - | $253.00 K(-69.0%) |
| Mar 2012 | - | $817.00 K(-45.1%) |
| Dec 2011 | $1.49 M(-424.2%) | $1.49 M(-36.3%) |
| Sep 2011 | - | $2.34 M(+4.0%) |
| Jun 2011 | - | $2.25 M(-15.7%) |
| Mar 2011 | - | $2.67 M(-680.8%) |
| Dec 2010 | -$459.00 K(-73.7%) | -$459.00 K(-26.3%) |
| Sep 2010 | - | -$623.00 K(+32.6%) |
| Jun 2010 | - | -$470.00 K(<-9900.0%) |
| Mar 2010 | - | $3000.00(-100.2%) |
| Dec 2009 | -$1.74 M(-16.0%) | -$1.74 M(-32.1%) |
| Sep 2009 | - | -$2.57 M(+12.0%) |
| Jun 2009 | - | -$2.29 M(+0.5%) |
| Mar 2009 | - | -$2.28 M(+9.9%) |
| Dec 2008 | -$2.08 M(-14.5%) | -$2.08 M(+16.2%) |
| Sep 2008 | - | -$1.79 M(+12.2%) |
| Jun 2008 | - | -$1.59 M(-34.8%) |
| Mar 2008 | - | -$2.44 M(+0.7%) |
| Dec 2007 | -$2.43 M(+33.7%) | -$2.43 M(+13.3%) |
| Sep 2007 | - | -$2.14 M(-29.1%) |
| Jun 2007 | - | -$3.02 M(+21.4%) |
| Mar 2007 | - | -$2.49 M(+75.3%) |
| Dec 2006 | -$1.82 M(-77.0%) | - |
| Sep 2006 | - | -$1.42 M(+96.3%) |
| Jun 2006 | - | -$724.00 K(-90.8%) |
| Mar 2006 | - | -$7.91 M(+4741.3%) |
| Mar 2006 | -$7.91 M(-1222.9%) | - |
| Dec 2005 | - | -$163.40 K(-172.7%) |
| Sep 2005 | - | $224.70 K(-47.9%) |
| Jun 2005 | - | $431.60 K(-38.7%) |
| Mar 2005 | $704.50 K(-2343.6%) | $704.50 K(+252.6%) |
| Dec 2004 | - | $199.80 K(+430.0%) |
| Sep 2004 | - | $37.70 K(-40.2%) |
| Jun 2004 | - | $63.00 K(-300.6%) |
| Mar 2004 | -$31.40 K(-253.9%) | -$31.40 K(-5333.3%) |
| Dec 2003 | - | $600.00(-87.8%) |
| Sep 2003 | - | $4900.00(-59.8%) |
| Jun 2003 | - | $12.20 K(-40.2%) |
| Mar 2003 | $20.40 K(-60.9%) | $20.40 K(-30.4%) |
| Dec 2002 | - | $29.30 K(-17.2%) |
| Sep 2002 | - | $35.40 K(-18.8%) |
| Jun 2002 | - | $43.60 K |
| Mar 2002 | $52.20 K | - |
FAQ
- What is Brainstorm Cell Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual shareholders equity year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly shareholders equity year-on-year change?
What is Brainstorm Cell Therapeutics annual stockholders equity?
The current annual shareholders equity of BCLI is -$4.86 M
What is the all time high annual shareholders equity for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual stockholders equity is $35.46 M
What is Brainstorm Cell Therapeutics annual shareholders equity year-on-year change?
Over the past year, BCLI annual stockholders equity has changed by -$1.84 M (-61.13%)
What is Brainstorm Cell Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of BCLI is -$6.06 M
What is the all time high quarterly shareholders equity for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly stockholders equity is $36.20 M
What is Brainstorm Cell Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, BCLI quarterly stockholders equity has changed by -$2.53 M (-71.73%)